Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:MARCH6-UVRAG

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: MARCH6-UVRAG
	FusionPDB ID: 51706
	FusionGDB2.0 ID: 51706
		Hgene	Tgene
	Gene symbol	MARCH6	UVRAG
	Gene ID	10299	7405
	Gene name	membrane associated ring-CH-type finger 6	UV radiation resistance associated
	Synonyms	DOA10\|FAME3\|MARCH-VI\|MARCH6\|RNF176\|TEB4	DHTX\|VPS38\|p63
	Cytomap	5p15.2	11q13.5
	Type of gene	protein-coding	protein-coding
	Description	E3 ubiquitin-protein ligase MARCH6RING finger protein 176RING-type E3 ubiquitin transferase MARCH6doa10 homologmembrane associated ring finger 6membrane-associated RING finger protein 6membrane-associated RING-CH finger protein 6membrane-associated	UV radiation resistance-associated gene proteinbeclin 1 binding proteindisrupted in heterotaxy
	Modification date	20200313	20200313
	UniProtAcc	.	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000274140, ENST00000449913, ENST00000503788, ENST00000510792, ENST00000606497,	ENST00000538870, ENST00000525872, ENST00000356136, ENST00000528420, ENST00000531818, ENST00000532130, ENST00000533454, ENST00000539288,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	14 X 8 X 8=896	28 X 21 X 11=6468
	# samples	14	36
	** MAII score	log2(14/896*10)=-2.67807190511264 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(36/6468*10)=-4.16725086714399 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: MARCH6 [Title/Abstract] AND UVRAG [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: MARCH6 [Title/Abstract] AND UVRAG [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	MARCH6(10411649)-UVRAG(75826968), # samples:2
Anticipated loss of major functional domain due to fusion event.	MARCH6-UVRAG seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. MARCH6-UVRAG seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. MARCH6-UVRAG seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. MARCH6-UVRAG seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	MARCH6	GO:0010498	proteasomal protein catabolic process	15673284
Hgene	MARCH6	GO:0016567	protein ubiquitination	24449766
Hgene	MARCH6	GO:0043161	proteasome-mediated ubiquitin-dependent protein catabolic process	24449766
Hgene	MARCH6	GO:0070936	protein K48-linked ubiquitination	15673284
Tgene	UVRAG	GO:0071900	regulation of protein serine/threonine kinase activity	22542840
Tgene	UVRAG	GO:0097352	autophagosome maturation	28306502
Tgene	UVRAG	GO:0097680	double-strand break repair via classical nonhomologous end joining	22542840

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr5:10411649/chr11:75826968)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across MARCH6 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across UVRAG (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000449913	MARCH6	chr5	10411649	+	ENST00000356136	UVRAG	chr11	75826968	+	4525	1948	100	2742	880
ENST00000449913	MARCH6	chr5	10411649	+	ENST00000528420	UVRAG	chr11	75826968	+	3124	1948	100	2742	880
ENST00000449913	MARCH6	chr5	10411649	+	ENST00000533454	UVRAG	chr11	75826968	+	2830	1948	100	2742	880
ENST00000449913	MARCH6	chr5	10411649	+	ENST00000531818	UVRAG	chr11	75826968	+	3981	1948	100	2742	880
ENST00000449913	MARCH6	chr5	10411649	+	ENST00000532130	UVRAG	chr11	75826968	+	3113	1948	100	2742	880
ENST00000449913	MARCH6	chr5	10411649	+	ENST00000539288	UVRAG	chr11	75826968	+	2830	1948	100	2742	880
ENST00000503788	MARCH6	chr5	10411649	+	ENST00000356136	UVRAG	chr11	75826968	+	4341	1764	87	2558	823
ENST00000503788	MARCH6	chr5	10411649	+	ENST00000528420	UVRAG	chr11	75826968	+	2940	1764	87	2558	823
ENST00000503788	MARCH6	chr5	10411649	+	ENST00000533454	UVRAG	chr11	75826968	+	2646	1764	87	2558	823
ENST00000503788	MARCH6	chr5	10411649	+	ENST00000531818	UVRAG	chr11	75826968	+	3797	1764	87	2558	823
ENST00000503788	MARCH6	chr5	10411649	+	ENST00000532130	UVRAG	chr11	75826968	+	2929	1764	87	2558	823
ENST00000503788	MARCH6	chr5	10411649	+	ENST00000539288	UVRAG	chr11	75826968	+	2646	1764	87	2558	823
ENST00000274140	MARCH6	chr5	10411649	+	ENST00000356136	UVRAG	chr11	75826968	+	4605	2028	36	2822	928
ENST00000274140	MARCH6	chr5	10411649	+	ENST00000528420	UVRAG	chr11	75826968	+	3204	2028	36	2822	928
ENST00000274140	MARCH6	chr5	10411649	+	ENST00000533454	UVRAG	chr11	75826968	+	2910	2028	36	2822	928
ENST00000274140	MARCH6	chr5	10411649	+	ENST00000531818	UVRAG	chr11	75826968	+	4061	2028	36	2822	928
ENST00000274140	MARCH6	chr5	10411649	+	ENST00000532130	UVRAG	chr11	75826968	+	3193	2028	36	2822	928
ENST00000274140	MARCH6	chr5	10411649	+	ENST00000539288	UVRAG	chr11	75826968	+	2910	2028	36	2822	928
ENST00000510792	MARCH6	chr5	10411649	+	ENST00000356136	UVRAG	chr11	75826968	+	3703	1126	127	1920	597
ENST00000510792	MARCH6	chr5	10411649	+	ENST00000528420	UVRAG	chr11	75826968	+	2302	1126	127	1920	597
ENST00000510792	MARCH6	chr5	10411649	+	ENST00000533454	UVRAG	chr11	75826968	+	2008	1126	127	1920	597
ENST00000510792	MARCH6	chr5	10411649	+	ENST00000531818	UVRAG	chr11	75826968	+	3159	1126	127	1920	597
ENST00000510792	MARCH6	chr5	10411649	+	ENST00000532130	UVRAG	chr11	75826968	+	2291	1126	127	1920	597
ENST00000510792	MARCH6	chr5	10411649	+	ENST00000539288	UVRAG	chr11	75826968	+	2008	1126	127	1920	597

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000449913	ENST00000356136	MARCH6	chr5	10411649	+	UVRAG	chr11	75826968	+	0.001354023	0.99864596
ENST00000449913	ENST00000528420	MARCH6	chr5	10411649	+	UVRAG	chr11	75826968	+	0.001943705	0.9980563
ENST00000449913	ENST00000533454	MARCH6	chr5	10411649	+	UVRAG	chr11	75826968	+	0.002598401	0.9974016
ENST00000449913	ENST00000531818	MARCH6	chr5	10411649	+	UVRAG	chr11	75826968	+	0.001396748	0.9986033
ENST00000449913	ENST00000532130	MARCH6	chr5	10411649	+	UVRAG	chr11	75826968	+	0.001889755	0.9981103
ENST00000449913	ENST00000539288	MARCH6	chr5	10411649	+	UVRAG	chr11	75826968	+	0.002598401	0.9974016
ENST00000503788	ENST00000356136	MARCH6	chr5	10411649	+	UVRAG	chr11	75826968	+	0.001841711	0.9981583
ENST00000503788	ENST00000528420	MARCH6	chr5	10411649	+	UVRAG	chr11	75826968	+	0.002876381	0.99712366
ENST00000503788	ENST00000533454	MARCH6	chr5	10411649	+	UVRAG	chr11	75826968	+	0.00391674	0.99608326
ENST00000503788	ENST00000531818	MARCH6	chr5	10411649	+	UVRAG	chr11	75826968	+	0.001898741	0.9981013
ENST00000503788	ENST00000532130	MARCH6	chr5	10411649	+	UVRAG	chr11	75826968	+	0.002792206	0.9972078
ENST00000503788	ENST00000539288	MARCH6	chr5	10411649	+	UVRAG	chr11	75826968	+	0.00391674	0.99608326
ENST00000274140	ENST00000356136	MARCH6	chr5	10411649	+	UVRAG	chr11	75826968	+	0.000755518	0.99924445
ENST00000274140	ENST00000528420	MARCH6	chr5	10411649	+	UVRAG	chr11	75826968	+	0.001163057	0.99883693
ENST00000274140	ENST00000533454	MARCH6	chr5	10411649	+	UVRAG	chr11	75826968	+	0.001543072	0.99845695
ENST00000274140	ENST00000531818	MARCH6	chr5	10411649	+	UVRAG	chr11	75826968	+	0.000776806	0.99922323
ENST00000274140	ENST00000532130	MARCH6	chr5	10411649	+	UVRAG	chr11	75826968	+	0.001137905	0.99886215
ENST00000274140	ENST00000539288	MARCH6	chr5	10411649	+	UVRAG	chr11	75826968	+	0.001543072	0.99845695
ENST00000510792	ENST00000356136	MARCH6	chr5	10411649	+	UVRAG	chr11	75826968	+	0.001256507	0.9987435
ENST00000510792	ENST00000528420	MARCH6	chr5	10411649	+	UVRAG	chr11	75826968	+	0.001672937	0.9983271
ENST00000510792	ENST00000533454	MARCH6	chr5	10411649	+	UVRAG	chr11	75826968	+	0.00233197	0.99766797
ENST00000510792	ENST00000531818	MARCH6	chr5	10411649	+	UVRAG	chr11	75826968	+	0.001288458	0.9987116
ENST00000510792	ENST00000532130	MARCH6	chr5	10411649	+	UVRAG	chr11	75826968	+	0.001618749	0.99838126
ENST00000510792	ENST00000539288	MARCH6	chr5	10411649	+	UVRAG	chr11	75826968	+	0.00233197	0.99766797

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for MARCH6-UVRAG

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
MARCH6	chr5	10411649	UVRAG	chr11	75826968	1126	333	FQPYRRPLNFPLRLRYQHGLGTPDLR
MARCH6	chr5	10411649	UVRAG	chr11	75826968	1764	559	FQPYRRPLNFPLRLRYQHGLGTPDLR
MARCH6	chr5	10411649	UVRAG	chr11	75826968	1948	616	FQPYRRPLNFPLRLRYQHGLGTPDLR
MARCH6	chr5	10411649	UVRAG	chr11	75826968	2028	664	FQPYRRPLNFPLRLRYQHGLGTPDLR

Top

Potential FusionNeoAntigen Information of MARCH6-UVRAG in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

MARCH6-UVRAG_10411649_75826968.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B27:04	LRLRYQHGL	0.9996	0.8822	11	20
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B27:05	LRLRYQHGL	0.9996	0.9331	11	20
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B27:02	LRLRYQHGL	0.9996	0.8	11	20
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B27:07	LRLRYQHGL	0.9993	0.726	11	20
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B14:01	LRLRYQHGL	0.9778	0.9498	11	20
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B14:02	LRLRYQHGL	0.9778	0.9498	11	20
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B35:03	RPLNFPLRL	0.9398	0.7077	5	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B39:24	LRLRYQHGL	0.9142	0.6242	11	20
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B35:02	RPLNFPLRL	0.7814	0.7031	5	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B35:04	RPLNFPLRL	0.7814	0.7031	5	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B15:03	LNFPLRLRY	0.664	0.612	7	16
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B27:04	RRPLNFPLRL	0.9999	0.5152	4	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B27:05	RRPLNFPLRL	0.9999	0.6697	4	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-A31:02	RPLNFPLRLR	0.9207	0.5857	5	15
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-A74:03	RPLNFPLRLR	0.8754	0.564	5	15
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-A74:11	RPLNFPLRLR	0.8754	0.564	5	15
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-A74:09	RPLNFPLRLR	0.8754	0.564	5	15
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B27:04	YRRPLNFPLRL	0.9998	0.5706	3	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B27:05	YRRPLNFPLRL	0.9997	0.7448	3	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-A74:03	RRPLNFPLRLR	0.9821	0.6107	4	15
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-A74:11	RRPLNFPLRLR	0.9821	0.6107	4	15
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-A74:09	RRPLNFPLRLR	0.9821	0.6107	4	15
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B81:01	FPLRLRYQHGL	0.8417	0.5595	9	20
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B27:14	LRLRYQHGL	0.9996	0.8431	11	20
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C07:05	LRLRYQHGL	0.9934	0.9682	11	20
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C07:95	LRLRYQHGL	0.9897	0.7507	11	20
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B27:03	LRLRYQHGL	0.9788	0.9403	11	20
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B39:12	LRLRYQHGL	0.7854	0.95	11	20
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B35:12	RPLNFPLRL	0.7814	0.7031	5	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B39:10	RPLNFPLRL	0.7519	0.8552	5	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C15:04	LNFPLRLRY	0.5934	0.7864	7	16
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C04:14	RPLNFPLRL	0.2275	0.8304	5	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C06:03	LNFPLRLRY	0.056	0.9944	7	16
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C04:07	RPLNFPLRL	0.0252	0.7548	5	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B27:14	RRPLNFPLRL	0.9999	0.6426	4	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B27:03	RRPLNFPLRL	0.9964	0.7134	4	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C07:05	RRPLNFPLRL	0.9958	0.9234	4	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C07:95	RRPLNFPLRL	0.9957	0.5964	4	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C07:29	RRPLNFPLRL	0.9897	0.8863	4	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C07:13	RRPLNFPLRL	0.9857	0.7773	4	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C07:80	RRPLNFPLRL	0.9738	0.81	4	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C07:67	RRPLNFPLRL	0.9738	0.81	4	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C07:19	RRPLNFPLRL	0.9632	0.6238	4	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C07:46	RRPLNFPLRL	0.9617	0.738	4	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C07:10	RRPLNFPLRL	0.9585	0.8307	4	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-A31:01	RPLNFPLRLR	0.9191	0.5591	5	15
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B27:14	RLRYQHGLGT	0.8734	0.588	12	22
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C07:27	YRRPLNFPLRL	0.9989	0.8821	3	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C07:95	YRRPLNFPLRL	0.9988	0.5367	3	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C07:05	YRRPLNFPLRL	0.998	0.9466	3	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B27:03	YRRPLNFPLRL	0.9893	0.7857	3	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-A31:01	RRPLNFPLRLR	0.9877	0.5834	4	15
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C14:02	NFPLRLRY	0.6123	0.957	8	16
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C14:03	NFPLRLRY	0.6123	0.957	8	16
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B27:10	LRLRYQHGL	0.9996	0.9392	11	20
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B27:08	LRLRYQHGL	0.9996	0.8723	11	20
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B27:06	LRLRYQHGL	0.9994	0.9005	11	20
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B27:09	LRLRYQHGL	0.9993	0.9147	11	20
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C07:01	LRLRYQHGL	0.9911	0.7544	11	20
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B35:28	LNFPLRLRY	0.9505	0.9131	7	16
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B35:13	RPLNFPLRL	0.9374	0.7187	5	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C06:08	LRLRYQHGL	0.9053	0.9966	11	20
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C07:22	LRLRYQHGL	0.8332	0.7909	11	20
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B35:30	FPLRLRYQH	0.8164	0.665	9	18
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B35:17	FPLRLRYQH	0.8164	0.665	9	18
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B35:24	FPLRLRYQH	0.7821	0.8283	9	18
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B35:09	RPLNFPLRL	0.7814	0.7031	5	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B39:02	RPLNFPLRL	0.7453	0.8896	5	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B67:01	RPLNFPLRL	0.7222	0.624	5	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B39:31	LRLRYQHGL	0.7209	0.9508	11	20
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B18:04	LNFPLRLRY	0.6071	0.9212	7	16
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C15:09	LNFPLRLRY	0.5934	0.7864	7	16
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B18:07	LNFPLRLRY	0.3925	0.8742	7	16
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B18:08	LNFPLRLRY	0.3758	0.726	7	16
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B18:06	LNFPLRLRY	0.2939	0.9179	7	16
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B15:68	LNFPLRLRY	0.2775	0.5566	7	16
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C04:04	RPLNFPLRL	0.2389	0.6593	5	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C06:17	LRLRYQHGL	0.0916	0.9963	11	20
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C06:02	LRLRYQHGL	0.0916	0.9963	11	20
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B18:07	FPLRLRYQH	0.0424	0.871	9	18
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C04:01	RPLNFPLRL	0.0252	0.7548	5	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B27:10	RRPLNFPLRL	0.9999	0.7154	4	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B27:08	RRPLNFPLRL	0.9998	0.5745	4	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B27:09	RRPLNFPLRL	0.9994	0.6061	4	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C07:01	RRPLNFPLRL	0.998	0.5498	4	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C06:08	RRPLNFPLRL	0.9907	0.9566	4	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C07:22	RRPLNFPLRL	0.9847	0.685	4	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C07:02	RRPLNFPLRL	0.9738	0.81	4	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-A74:01	RPLNFPLRLR	0.8754	0.564	5	15
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C06:02	RRPLNFPLRL	0.8114	0.9831	4	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C06:17	RRPLNFPLRL	0.8114	0.9831	4	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B27:10	YRRPLNFPLRL	0.9998	0.7611	3	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B27:10	RRPLNFPLRLR	0.9998	0.7611	4	15
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B27:08	YRRPLNFPLRL	0.9997	0.6122	3	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B27:06	YRRPLNFPLRL	0.9996	0.5769	3	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C07:22	YRRPLNFPLRL	0.9974	0.6301	3	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-B27:09	YRRPLNFPLRL	0.9962	0.6865	3	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C06:08	YRRPLNFPLRL	0.9919	0.9624	3	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-A74:01	RRPLNFPLRLR	0.9821	0.6107	4	15
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C06:02	YRRPLNFPLRL	0.8727	0.9814	3	14
MARCH6-UVRAG	chr5	10411649	chr11	75826968	2028	HLA-C06:17	YRRPLNFPLRL	0.8727	0.9814	3	14

Top

Potential FusionNeoAntigen Information of MARCH6-UVRAG in HLA II

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene

Hchr

Hbp

Tgene

Tchr

Tbp

HLA II

FusionNeoAntigen peptide

Neoantigen start (at BP 13)

Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of MARCH6-UVRAG

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
6773	PLNFPLRLRYQHGL	MARCH6	UVRAG	chr5	10411649	chr11	75826968	2028

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of MARCH6-UVRAG

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	6773	PLNFPLRLRYQHGL	-6.79893	-6.91233
HLA-B14:02	3BVN	6773	PLNFPLRLRYQHGL	-4.87525	-5.91055
HLA-B52:01	3W39	6773	PLNFPLRLRYQHGL	-5.99057	-7.02587
HLA-B52:01	3W39	6773	PLNFPLRLRYQHGL	-4.54916	-4.66256
HLA-A11:01	4UQ2	6773	PLNFPLRLRYQHGL	-6.80217	-6.91557
HLA-A11:01	4UQ2	6773	PLNFPLRLRYQHGL	-6.23647	-7.27177
HLA-A24:02	5HGA	6773	PLNFPLRLRYQHGL	-8.70311	-8.81651
HLA-A24:02	5HGA	6773	PLNFPLRLRYQHGL	-5.62003	-6.65533
HLA-B27:05	6PYJ	6773	PLNFPLRLRYQHGL	-2.64244	-2.75584
HLA-B27:05	6PYJ	6773	PLNFPLRLRYQHGL	-2.41053	-3.44583
HLA-B44:05	3DX8	6773	PLNFPLRLRYQHGL	-5.78161	-5.89501
HLA-B44:05	3DX8	6773	PLNFPLRLRYQHGL	-4.08476	-5.12006

Top

Vaccine Design for the FusionNeoAntigens of MARCH6-UVRAG

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
MARCH6-UVRAG	chr5	10411649	chr11	75826968	11	20	LRLRYQHGL	CTCAGGCTAAGATATCAACATGGACTA
MARCH6-UVRAG	chr5	10411649	chr11	75826968	12	22	RLRYQHGLGT	AGGCTAAGATATCAACATGGACTAGGGACT
MARCH6-UVRAG	chr5	10411649	chr11	75826968	3	14	YRRPLNFPLRL	TACCGCCGACCTTTAAATTTTCCACTCAGGCTA
MARCH6-UVRAG	chr5	10411649	chr11	75826968	4	14	RRPLNFPLRL	CGCCGACCTTTAAATTTTCCACTCAGGCTA
MARCH6-UVRAG	chr5	10411649	chr11	75826968	4	15	RRPLNFPLRLR	CGCCGACCTTTAAATTTTCCACTCAGGCTAAGA
MARCH6-UVRAG	chr5	10411649	chr11	75826968	5	14	RPLNFPLRL	CGACCTTTAAATTTTCCACTCAGGCTA
MARCH6-UVRAG	chr5	10411649	chr11	75826968	5	15	RPLNFPLRLR	CGACCTTTAAATTTTCCACTCAGGCTAAGA
MARCH6-UVRAG	chr5	10411649	chr11	75826968	7	16	LNFPLRLRY	TTAAATTTTCCACTCAGGCTAAGATAT
MARCH6-UVRAG	chr5	10411649	chr11	75826968	8	16	NFPLRLRY	AATTTTCCACTCAGGCTAAGATAT
MARCH6-UVRAG	chr5	10411649	chr11	75826968	9	18	FPLRLRYQH	TTTCCACTCAGGCTAAGATATCAACAT
MARCH6-UVRAG	chr5	10411649	chr11	75826968	9	20	FPLRLRYQHGL	TTTCCACTCAGGCTAAGATATCAACATGGACTA

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene

Hchr

Hbp

Tchr

Tbp

Start in +/-13AA

End in +/-13AA

FusionNeoAntigen peptide

FusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of MARCH6-UVRAG

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
OV	MARCH6-UVRAG	chr5	10411649	ENST00000274140	chr11	75826968	ENST00000356136	TCGA-24-1930-01A

Top

Potential target of CAR-T therapy development for MARCH6-UVRAG

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Hgene

MARCH6

chr5:10411649

chr11:75826968

ENST00000274140

143_163

632

911.0

Transmembrane

Helical

Hgene

MARCH6

chr5:10411649

chr11:75826968

ENST00000274140

284_304

632

911.0

Transmembrane

Helical

Hgene

MARCH6

chr5:10411649

chr11:75826968

ENST00000274140

337_357

632

911.0

Transmembrane

Helical

Hgene

MARCH6

chr5:10411649

chr11:75826968

ENST00000274140

377_397

632

911.0

Transmembrane

Helical

Hgene

MARCH6

chr5:10411649

chr11:75826968

ENST00000274140

422_442

632

911.0

Transmembrane

Helical

Hgene

MARCH6

chr5:10411649

chr11:75826968

ENST00000274140

481_501

632

911.0

Transmembrane

Helical

Hgene

MARCH6

chr5:10411649

chr11:75826968

ENST00000274140

520_540

632

911.0

Transmembrane

Helical

Hgene

MARCH6

chr5:10411649

chr11:75826968

ENST00000274140

92_112

632

911.0

Transmembrane

Helical

Hgene

MARCH6

chr5:10411649

chr11:75826968

ENST00000449913

143_163

584

863.0

Transmembrane

Helical

Hgene

MARCH6

chr5:10411649

chr11:75826968

ENST00000449913

284_304

584

863.0

Transmembrane

Helical

Hgene

MARCH6

chr5:10411649

chr11:75826968

ENST00000449913

337_357

584

863.0

Transmembrane

Helical

Hgene

MARCH6

chr5:10411649

chr11:75826968

ENST00000449913

377_397

584

863.0

Transmembrane

Helical

Hgene

MARCH6

chr5:10411649

chr11:75826968

ENST00000449913

422_442

584

863.0

Transmembrane

Helical

Hgene

MARCH6

chr5:10411649

chr11:75826968

ENST00000449913

481_501

584

863.0

Transmembrane

Helical

Hgene

MARCH6

chr5:10411649

chr11:75826968

ENST00000449913

520_540

584

863.0

Transmembrane

Helical

Hgene

MARCH6

chr5:10411649

chr11:75826968

ENST00000449913

92_112

584

863.0

Transmembrane

Helical

Hgene

MARCH6

chr5:10411649

chr11:75826968

ENST00000503788

143_163

527

806.0

Transmembrane

Helical

Hgene

MARCH6

chr5:10411649

chr11:75826968

ENST00000503788

284_304

527

806.0

Transmembrane

Helical

Hgene

MARCH6

chr5:10411649

chr11:75826968

ENST00000503788

337_357

527

806.0

Transmembrane

Helical

Hgene

MARCH6

chr5:10411649

chr11:75826968

ENST00000503788

377_397

527

806.0

Transmembrane

Helical

Hgene

MARCH6

chr5:10411649

chr11:75826968

ENST00000503788

422_442

527

806.0

Transmembrane

Helical

Hgene

MARCH6

chr5:10411649

chr11:75826968

ENST00000503788

481_501

527

806.0

Transmembrane

Helical

Hgene

MARCH6

chr5:10411649

chr11:75826968

ENST00000503788

92_112

527

806.0

Transmembrane

Helical

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to MARCH6-UVRAG

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to MARCH6-UVRAG

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)